SARS-CoV-2, the virus that causes COVID-19, uses a surface spike protein to latch onto human cells and initiate infection. But heparin, a blood thinner also available in non-anticoagulant
Tremfya is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin (IL)-23 and prevents its interaction with the IL-23 receptor, as per Janssen.
60P collaborated with Biointelect, 360 Biolabs, Biocelect, and Certara to conduct testing on tafenoquine. In vitro testing and modeling and simulation with Certara’s Simcyp Simulator demonstrate that tafenoquine
“We are pleased to have treated the first patient in our Phase 1 trial of RP-L301, marking an important step forward in addressing a high unmet need for
The deal gives Roche exclusive rights for the co-development and commercialisation of pralsetinib outside the US with the exclusion of Mainland China, Hong Kong, Macau, and Taiwan. In
“With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including cell and gene therapies
The first group of volunteers who were administered the coronavirus vaccine candidate will be discharged this week, reported Sputnik, citing the university’s Institute for Translational Medicine and Biotechnology
There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in
Proceeds will advance the company’s lead candidate VOR33 into clinical trials, deepen its portfolio, and accelerate the validation of additional targets for its scientific platform, which is designed
The trial of EIDD-2801 will be held using a newly launched Covid-19 drug testing platform called AGILE, which has been developed in the UK by the University of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.